09.07.2020 Moderna Daily Analysis

09.07.2020 Moderna Daily Analysis

MRNA is in the midst of its phase 1 trial and their interim data was positive. The company reported that binding and neutralizing antibody counts of participants were at the same level or higher than in patients who had recovered from the coronavirus. Although, it was a small sample size with only 8 participants. MRNA plans to begin phase 2 trials later this month with 30,000 participants. People are hopeful specifically about the increase in neutralizing antibodies which gives the body stronger defense than just binding antibodies. All of Moderna’s products are predicated on its use of messenger RNA to deliver instructions to cells.  Since all of the company’s other products are in a preclinical phase but also depend on the use of messenger RNA, this is a major opportunity for MRNA to prove that its technology is viable and can deliver effective outcomes.